Ignite Creation Date:
2024-05-06 @ 3:06 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04523662
Status:
UNKNOWN
Last Update Posted:
2020-08-21
First Post:
2020-08-06
Brief Title:
Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer
Sponsor:
Beijing Tsinghua Chang Gung Hospital
Organization:
Beijing Tsinghua Chang Gung Hospital
Study Overview
Official Title:
Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer With Extrahepatic Metastasis
Status:
UNKNOWN
Status Verified Date:
2020-08
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Literature has shown that radiotherapy can promote tumor antigen presentation mobilize and activate T cells by enhancing activation signals and blocking inhibitory signals It can also lead to the normalization of blood vessels in the tumor microenvironment and the increase of CXCL16 and other chemokines to activate T cells The cells infiltrate the tumor tissues better and promote the killing activity of T cells Therefore the combined application of radiotherapy and immunotherapy may have a synergistic effect Apatinib is a small molecule tyrosine protein kinase inhibitor for VEGFR Low-dose apatinib can induce the normalization of abnormal blood vessels in tumors effectively increase the infiltration of lymphocytes in tumor tissues and block immunosuppressive myeloid cells Recruitment reverse the immunosuppressive state effectively reduce the level of TGF-β and make the tumor environment tend to have an immune support phenotype Apatinib combined with PD-1 antibody karelizumab has been confirmed in a phase I study to have good efficacy and safety in patients with advanced liver cancer Therefore this study intends to use the PD-1 antibody carrelizumab combined with apatinib and radiotherapy to treat patients with advanced liver cancer with extrahepatic metastasis to evaluate the effectiveness and safety of the combined therapy and to provide new clinical treatments for liver cancer Evidence-based medicine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None